Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy
- Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy: COMMENTARY. Basu, Ananda // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p47
The article offers the author's comments on a clinical trial that states that vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy. While the author acknowledges the positive results, he cautions that the dipeptidyl peptidase or...
- Saxagliptin. Dhillon, Sohita; Weber, Juliane // Drugs;2009, Vol. 69 Issue 15, p2103
â–´Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-l (GLP- 1) and glucose-dependent insulinotropic polypeptide. This increases GLP-l levels, stimulates...
- New from NPG. // Nature Medicine;Apr2013, Vol. 19 Issue 4, p417
This section offers medical research news briefs on topics such as functional receptor role of dipeptidyl peptidase 4 in the new human coronavirus EMC, blocking function of ATP-competitive kinase inhibitors, and identification of new loci associated with age-related macular degeneration (AMD).
- Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review. Wong, Martin C. S.; Wang, Harry H. X.; Kwan, Mandy W. M.; Zhang, Daisy D. X.; Liu, Kirin Q. L.; Chan, Sky W. M.; Fan, Carmen K. M.; Fong, Brian C. Y.; Li, Shannon T. S.; Griffiths, Sian M. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug...
- Investigational DPP-IV inhibitor at various doses reduced HbA1c in type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Nov2012, Vol. 10 Issue 11, p31
The article reports on a study which found that an investigational, once-weekly dipeptidyl peptidase-intravenous (DPP-IV) inhibitor significantly lowered HbA1c in type 2 diabetes.
- Sitagliptin and Vildagliptin: Efficacy of Therapy in Type 2 Diabetes. Kirk, Julienne K.; Oldham, Elizabeth C. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2008, Vol. 2 Issue 3, p162
The clinical efficacy and tolerability of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is supported by published clinical trials. Primary literature and review articles were obtained via a Pubmed search (2002-2008) using the search terms diabetes, sitagliptin,...
- Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. MONAMI, MATTEO; DICEMBRINI, ILARIA; ANTENORE, ALESSANDRO; MANNUCCI, EDOARDO // Diabetes Care;Nov2011, Vol. 34 Issue 11, p2474
OBJECTIVE--Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far....
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis. Cheng, Dongsheng; Fei, Yang; Liu, Yumei; Li, Junhui; Chen, Yuqiang; Wang, Xiaoxia; Wang, Niansong // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1
Objective: To perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors (â€œgliptinsâ€) for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment. Methods: All available...
- Erratum. // Diabetes Care;Jan2014, Vol. 37 Issue 1, following p312
A correction to the article "Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials" in the 2014 issue is presented.